Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.37 |
| ▸ | FDPS | P14324 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22050575 | 0.96 | OPRM1 (0.37) | OPRM1OPRD1OPRK1OPRL1FDPS | |
| SCHEMBL24777893 | 0.94 | OPRM1 (0.39) | OPRM1OPRD1OPRK1OPRL1FDPS | |
| SCHEMBL24777653 | 0.94 | OPRM1 (0.39) | OPRM1OPRD1OPRK1OPRL1FDPS | |
| SCHEMBL22282367 | 0.93 | OPRM1 (0.38) | OPRM1OPRD1OPRK1OPRL1FDPS | |
| SCHEMBL21007972 | 0.86 | OPRM1 (0.37) | OPRM1OPRD1OPRK1OPRL1FDPS | |
| SCHEMBL23806516 | 0.85 | S1PR1 (0.44) | — | |
| SCHEMBL25812980 | 0.84 | FDPS (0.37) | OPRM1OPRD1OPRK1OPRL1FDPS | |
| SCHEMBL25812961 | 0.83 | OPRM1 (0.34) | OPRM1OPRD1OPRK1OPRL1DNM1 | |
| SCHEMBL23008461 | 0.83 | OPRM1 (0.34) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL20676135 | 0.83 | OPRM1 (0.35) | OPRM1OPRD1OPRK1OPRL1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382889-A1 | COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20220073504-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382889-A1 | COMPOUNDS FOR INHIBITING KIF18A | KIF18A, KIF18B, KIF2C | OPRM1 4803/4885OPRD1 4818/4885OPRK1 4436/4885 |
| US-20220073504-A1 | KIF18A INHIBITORS | KIF18A, KIF18B, KIF15 | OPRM1 4704/4885OPRD1 4567/4885OPRK1 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.